Top Page
New China Life Insurance Co., Ltd. Class H
(1336)
New China Life Insurance Co., Ltd. Class H (1336) vs. iShares MSCI Hong Kong ETF (EWH)
New China Life Insurance Co., Ltd. Class H Business Overview & Revenue Model
New China Life Insurance Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 109.23B | 68.01B | 72.19B | 214.34B | 222.00B | 206.28B |
| Gross Profit | 109.23B | 68.01B | 72.19B | 214.34B | 222.00B | 206.28B |
| EBITDA | 6.51B | 0.00 | 6.15B | 8.29B | 0.00 | 0.00 |
| Net Income | 27.17B | 26.23B | 8.71B | 9.82B | 14.95B | 14.29B |
Balance Sheet | ||||||
| Total Assets | 1.75T | 1.69T | 1.40T | 1.26T | 1.13T | 1.00T |
| Cash, Cash Equivalents and Short-Term Investments | 41.66B | 38.46B | 21.81B | 393.24B | 418.90B | 439.70B |
| Total Debt | 31.30B | 31.10B | 21.02B | 10.86B | 11.04B | 11.06B |
| Total Liabilities | 1.67T | 1.60T | 1.30T | 1.15T | 1.02T | 902.70B |
| Stockholders Equity | 79.85B | 96.24B | 105.07B | 102.88B | 108.50B | 101.67B |
Cash Flow | ||||||
| Free Cash Flow | 63.72B | 95.19B | 89.46B | 87.60B | 70.59B | 64.14B |
| Operating Cash Flow | 23.45B | 96.29B | 91.55B | 89.39B | 73.85B | 67.18B |
| Investing Cash Flow | -175.30B | -141.77B | -156.65B | -90.47B | -106.53B | -67.73B |
| Financing Cash Flow | 99.38B | 62.03B | 69.29B | 2.84B | 35.24B | 1.97B |
New China Life Insurance Co., Ltd. Class H Technical Analysis
New China Life Insurance Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $1.04T | 7.22 | 6.91% | 11.71% | 37.04% | ||
78 Outperform | $392.78B | 5.80 | 17.85% | 2.06% | 4.62% | 81.63% | |
78 Outperform | $752.51B | 14.85 | 16.75% | 3.69% | 7.04% | 88.41% | |
75 Outperform | HK$184.39B | 4.88 | 26.08% | 2.09% | -43.77% | ― | |
75 Outperform | $1.12T | 4.85 | 22.83% | 2.41% | 5.96% | 124.20% | |
70 Outperform | $363.55B | 5.89 | 16.47% | 4.17% | 11.99% | 54.60% | |
67 Neutral | $16.66B | 11.44 | 9.71% | 3.92% | 11.61% | -10.70% |
New China Life Insurance Co., Ltd. Class H Corporate Events
New China Life Insurance Co., Ltd. has announced a proposed capital contribution of up to RMB10 billion to subscribe to units of a new equity private securities investment fund. This fund, tentatively named Guofeng Xinghua Honghu Zhiyuan Private Securities Investment Fund II, aims to achieve stable dividend returns through long-term investment strategies. The proposed subscription is considered a discloseable transaction under Hong Kong’s Listing Rules, and while it does not require shareholder approval, it is subject to regulatory procedures and carries a degree of uncertainty. The fund’s total size is RMB20 billion, with China Life also contributing an equal amount.
New China Life Insurance Co., Ltd. reported a significant increase in its financial performance for the first quarter of 2025, with operating income rising by 26.1% and net profit attributable to shareholders increasing by 19.0% compared to the same period in 2024. Despite a decrease in net cash flows from operating activities, the company’s total assets grew by 3.6%, indicating a strong market position and potential positive implications for stakeholders.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB73,218.42 million for the first quarter of 2025, marking a 28% increase year on year. This growth is attributed to the company’s ongoing reforms and strategic enhancements in its product and service offerings, which are expected to provide strong momentum for future business expansion.
New China Life Insurance Co., Ltd. has announced a board meeting scheduled for April 29, 2025, to review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will determine the company’s financial performance for the quarter, potentially impacting its market positioning and stakeholder interests.
New China Life Insurance Co., Ltd. has received approval from the National Financial Regulatory Administration for amendments to its Articles of Association, as decided in the 2023 Annual General Meeting. These amendments align with relevant laws, regulations, and the company’s practices, and will take effect immediately, potentially impacting the company’s governance and regulatory compliance.
New China Life Insurance Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board is structured with a chairman, executive directors, non-executive directors, and independent non-executive directors, overseeing five committees that focus on strategy, investment, audit, nomination and remuneration, and risk management. This announcement underscores the company’s commitment to robust governance and strategic oversight, which is crucial for maintaining its competitive edge and ensuring stakeholder confidence.
New China Life Insurance Co., Ltd. announced the ratification of Ms. MAO Sixue’s qualification as a non-executive director by the National Financial Regulatory Administration. Ms. MAO will serve as the chairman of the Investment Committee and a member of the Audit and Related Party Transaction Control Committee, with her term commencing on 26 March 2025. This appointment is part of the company’s strategic leadership structuring, potentially impacting its governance and investment strategies.
New China Life Insurance Co., Ltd. held its second extraordinary general meeting of 2025 on March 31, 2025, in Beijing. The meeting, which complied with PRC laws and Hong Kong Listing Rules, involved both onsite and online voting for A share shareholders. All incumbent directors and supervisors attended, with Computershare Hong Kong Investor Services Limited serving as the scrutineer. The meeting saw participation from 570 shareholders and proxies, representing 50.72% of the company’s total voting shares, with no restrictions or abstentions required under the Hong Kong Listing Rules.
New China Life Insurance Co., Ltd. has announced a final cash dividend of RMB 1.99 per share for the financial year ending December 31, 2024. The payment date for this dividend is set for August 8, 2025, with further details regarding shareholder approval and other related information to be announced. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders.
New China Life Insurance Co., Ltd. announced its audited financial results for the year ending December 31, 2024, which were approved by the board and audited by Deloitte Touche Tohmatsu. The company plans to distribute a total dividend of RMB7,893 million for 2024, representing approximately 30.1% of its net profit attributable to shareholders, pending approval at the shareholders’ general meeting. The announcement underscores the company’s commitment to transparency and shareholder returns, highlighting its robust financial performance and strategic risk management efforts.
New China Life Insurance Co., Ltd. has announced an upcoming board meeting scheduled for March 27, 2025. The meeting will address several key issues, including the approval of the company’s annual results for 2024, the publication of these results, and the consideration of a final dividend distribution. This meeting is significant as it will impact the company’s financial disclosures and dividend policy, which are critical for stakeholders and investors.
New China Life Insurance Co., Ltd. reported an accumulated gross premium income of RMB51,124.31 million for the first two months of 2025, marking a 29% increase year-on-year. This growth is attributed to enhanced management of distribution channels and the performance of high-performing agents, reflecting the positive impact of the company’s ongoing reform and innovation efforts.
New China Life Insurance Co., Ltd. has announced the convening of its second extraordinary general meeting of 2025 to discuss and potentially approve a proposal for the issuance of domestic undated capital bonds. This meeting, scheduled for March 31, 2025, will involve both onsite and online voting, reflecting the company’s strategic financial planning and potential implications for shareholders and market positioning.
New China Life Insurance Company Ltd. announced adjustments to the composition of its board committees, with key appointments including Ms. MAO Sixue as chairman of the Investment Committee and Mr. ZHUO Zhi as a member of several committees. These changes, pending regulatory approval, are expected to impact the company’s governance and strategic direction, potentially influencing its market positioning and stakeholder relations.
New China Life Insurance Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The board comprises executive, non-executive, and independent non-executive directors, with five committees established to oversee various aspects of the company’s operations. This announcement reflects the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive position in the insurance industry.
New China Life Insurance Co., Ltd. reported a significant increase in its accumulated gross premium income for January 2025, reaching RMB39,448.98 million, which marks a 32% increase year on year. This substantial growth reflects the company’s effective reform and development strategies, with improvements in business channels and an increasing number of high-performing agents, indicating a positive impact on its market position and potential benefits for stakeholders.
New China Life Insurance Company Ltd. announced the resignation of Mr. HE Xingda from his roles as a non-executive director and chairman of various board committees due to work-related reasons. His departure will temporarily cause the board to fall below regulatory requirements, but he will maintain his responsibilities until a new director is appointed and approved. The company has expressed gratitude for his contributions, and Mr. HE confirmed no disagreements with the board, ensuring a smooth transition.